全文获取类型
收费全文 | 58073篇 |
免费 | 8406篇 |
国内免费 | 1640篇 |
专业分类
耳鼻咽喉 | 223篇 |
儿科学 | 1195篇 |
妇产科学 | 726篇 |
基础医学 | 5574篇 |
口腔科学 | 2482篇 |
临床医学 | 8534篇 |
内科学 | 6856篇 |
皮肤病学 | 930篇 |
神经病学 | 2799篇 |
特种医学 | 940篇 |
外国民族医学 | 9篇 |
外科学 | 5119篇 |
综合类 | 9850篇 |
现状与发展 | 8篇 |
一般理论 | 26篇 |
预防医学 | 5277篇 |
眼科学 | 932篇 |
药学 | 6896篇 |
476篇 | |
中国医学 | 5327篇 |
肿瘤学 | 3940篇 |
出版年
2024年 | 315篇 |
2023年 | 1711篇 |
2022年 | 2785篇 |
2021年 | 4200篇 |
2020年 | 4408篇 |
2019年 | 3279篇 |
2018年 | 3006篇 |
2017年 | 3256篇 |
2016年 | 3129篇 |
2015年 | 2758篇 |
2014年 | 4352篇 |
2013年 | 4615篇 |
2012年 | 3537篇 |
2011年 | 3608篇 |
2010年 | 2738篇 |
2009年 | 2415篇 |
2008年 | 2324篇 |
2007年 | 2370篇 |
2006年 | 2059篇 |
2005年 | 1699篇 |
2004年 | 1482篇 |
2003年 | 1327篇 |
2002年 | 1087篇 |
2001年 | 883篇 |
2000年 | 700篇 |
1999年 | 539篇 |
1998年 | 467篇 |
1997年 | 443篇 |
1996年 | 379篇 |
1995年 | 290篇 |
1994年 | 306篇 |
1993年 | 189篇 |
1992年 | 217篇 |
1991年 | 172篇 |
1990年 | 150篇 |
1989年 | 144篇 |
1988年 | 135篇 |
1987年 | 118篇 |
1986年 | 78篇 |
1985年 | 92篇 |
1984年 | 76篇 |
1983年 | 41篇 |
1982年 | 49篇 |
1981年 | 42篇 |
1980年 | 35篇 |
1979年 | 23篇 |
1978年 | 12篇 |
1977年 | 16篇 |
1976年 | 18篇 |
1975年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
32.
A. Cattapan K. Browne D.M. Halperin A. Di Castri P. Fullsack J. Graham J.M. Langley B.A. Taylor S.A. McNeil S.A. Halperin 《Vaccine》2019,37(2):289-295
Introduction/Hypothesis
Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014–2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.Methods
An online survey which included participants’ prior experience with clinical trials, motivations to participate (including financial incentives), and demographic information was developed to examine the motivations of healthy participants in two phase 1 clinical vaccine trials conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia. Participants were invited via email to complete the online survey. Readability and clarity were assessed through pilot testing.Results
A total of 49 (55.7%) of 88 participants of the two studies completed the survey (22 [55%] of 40 participants from the Ebola vaccine study and 27 [56.3%] of 48 from the adjuvanted influenza vaccine study). Motivations that were most frequently ranked among participants' top three in both trials were (1) wanting to contribute to the health of others, (2) wanting to participate in something important, (3) wanting to contribute to the advancement of science, and (4) wanting to receive an incentive such as money or a tablet.Conclusions/Recommendations
Although media attention and financial compensation were more often cited by Ebola vaccine trial participants as a reason to participate, both altruistic and self-interested factors were important motivations for participants in their decision to participate in a phase 1 vaccine clinical trial. 相似文献33.
Mt D. Dbrssy Chockalingam Ramanathan Danesh Ashouri Vajari Yixin Tong Thomas Schlaepfer Volker A. Coenen 《The European journal of neuroscience》2021,53(1):89-113
Deep brain stimulation (DBS) in psychiatric illnesses has been clinically tested over the past 20 years. The clinical application of DBS to the superolateral branch of the medial forebrain bundle in treatment‐resistant depressed patients—one of several targets under investigation—has shown to be promising in a number of uncontrolled open label trials. However, there are remain numerous questions that need to be investigated to understand and optimize the clinical use of DBS in depression, including, for example, the relationship between the symptoms, the biological substrates/projections and the stimulation itself. In the context of precision and customized medicine, the current paper focuses on clinical and experimental research of medial forebrain bundle DBS in depression or in animal models of depression, demonstrating how clinical and scientific progress can work in tandem to test the therapeutic value and investigate the mechanisms of this experimental treatment. As one of the hypotheses is that depression engenders changes in the reward and motivational networks, the review looks at how stimulation of the medial forebrain bundle impacts the dopaminergic system. 相似文献
34.
Ramya C. Mosarla Muthiah Vaduganathan Arman Qamar Javid Moslehi Gregory Piazza Robert P. Giugliano 《Journal of the American College of Cardiology》2019,73(11):1336-1349
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer. 相似文献
35.
36.
Bacterial keratitis continues to be one of the leading causes of corneal blindness in the developed as well as the developing world, despite swift progress since the dawn of the “anti-biotic era”. Although, we have expeditiously developed our understanding about the different causative organisms and associated pathology leading to keratitis, extensive gaps in knowledge continue to dampen the efforts required for early and accurate diagnosis, and management in these patients, resulting in poor clinical outcomes. The ability of the causative bacteria to subdue the therapeutic challenge stems from their large genome encoding complex regulatory networks, variety of unique virulence factors, and rapid secretion of tissue damaging proteases and toxins.In this review article, we provide an overview of the established diagnostic techniques and therapeutics for keratitis caused by various bacteria. We extensively report the recent in-roads through novel tools for accurately diagnosing mono- and poly-bacterial corneal infections. Furthermore, we outline the recent progress by our groups and others in understanding the sub-cellular genomic changes that lead to antibiotic resistance in these organisms. Finally, we discuss in detail, the novel therapies and drug delivery systems in development for the efficacious management of bacterial keratitis. 相似文献
37.
目的:探讨中西医结合护理干预妊娠晚期合并急性单纯性阑尾炎的临床疗效。方法:将2017 年9 月—2018 年12月于我院接受中西医结合保守治疗的31 例妊娠晚期合并急性单纯性阑尾炎患者作为研究对象,按随机数表法随机分为中西医结合护理组(观察组16 例)与常规护理组(对照组15 例),对照组采取常规护理措施,观察组在对照组的基础上增加中西医结合护理措施,对比两组患者的临床疗效。结果:观察组患者的心理状态变化、新生儿体质状况以及临床疗效等指标等情况均明显优于对照组,且组间对比差异显著有统计学意义(P < 0.05)。结论:中西医结合护理对妊娠晚期合并急性单纯性阑尾炎有较好的临床效果,可减少、甚至避免孕妇因合并急性阑尾炎而造成的打击和创伤。 相似文献
38.
随着我国医疗机构临床药师队伍的不断壮大,其在医疗服务中发挥着越来越重要的作用,对其工作进行绩效考核也是当今医疗领域的重要内容。以现有文献为基础,对国内外临床药师绩效考核体系进行分析,发现现有体系可分为为基于临床药师职责、基于临床药师业务流程、国外临床药师绩效考核体系三个方面;通过结合医疗机构的实际情况对现有绩效考核体系进行分析,发现存在考核指标和标准确定困难、考核难以做到实时性和延续性等问题,并针对这些问题提出清晰职责定位、重视临床药师价值体现等修改说明。 相似文献
39.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献40.
Javed A. Shaik Nima Estharabadi Ronda S. Farah Maria K. Hordinsky 《Experimental dermatology》2020,29(10):1004-1011
Platelet α-granules release growth factors (GFs) that promote healing and tissue regeneration. Platelet-rich plasma (PRP) is shown to be beneficial in treating alopecia, and however, clinical response can be inconsistent. Due to several fold enrichment of platelets secreting large quantities of GFs following PRP injections, heterogeneity in amounts of GFs secreted by platelets may contribute to inconsistent clinical responses. Herein, we evaluated factors that could potentially contribute to heterogeneous secretion of GFs by platelets. We measured platelet secretion of transforming growth factor beta1 (TGFβ1), platelet-derived growth factor (PDGF-BB), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF2) in aliquots of de-identified PRP samples from female patients undergoing therapy in the hair disease clinic. Although secretion of GFs by platelets was comparable in PRP samples of patients with non-cicatricial and cicatricial alopecia, a Shapiro-Wilk test for normal distribution indicated significant variability across all patient samples. The amount of GF secreted by platelets was comparable when PRP prepared from two FDA-cleared devices with distinct techniques were compared. We provide evidence of platelets secreting heterogeneous amounts of GFs within each sample as high and low secretion of random factors could be simultaneously detected. These results suggest inherent heterogeneity in secretion of GFs by platelets in patient samples that are not influenced by the device used to prepare PRP. Since some GFs could have antagonistic effects on hair growth, a balance between amounts of growth promoting and inhibiting factors may be crucial in determining clinical response to PRP therapy. 相似文献